Primecap Management Co. CA Has $162.22 Million Holdings in Glaukos Co. (NYSE:GKOS)

Primecap Management Co. CA grew its holdings in Glaukos Co. (NYSE:GKOS - Free Report) by 2.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,245,185 shares of the medical instruments supplier's stock after acquiring an additional 24,370 shares during the quarter. Primecap Management Co. CA owned 2.26% of Glaukos worth $162,223,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of GKOS. Intech Investment Management LLC increased its stake in Glaukos by 79.9% during the third quarter. Intech Investment Management LLC now owns 20,462 shares of the medical instruments supplier's stock valued at $2,666,000 after acquiring an additional 9,088 shares during the period. Jennison Associates LLC acquired a new stake in shares of Glaukos during the 3rd quarter worth approximately $792,000. B. Metzler seel. Sohn & Co. Holding AG bought a new stake in shares of Glaukos during the third quarter valued at approximately $1,347,000. Pathstone Holdings LLC raised its stake in shares of Glaukos by 6.3% in the third quarter. Pathstone Holdings LLC now owns 22,449 shares of the medical instruments supplier's stock valued at $2,925,000 after purchasing an additional 1,326 shares in the last quarter. Finally, First Turn Management LLC bought a new position in Glaukos in the third quarter worth $12,520,000. 99.04% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

GKOS has been the topic of several analyst reports. Needham & Company LLC boosted their price target on shares of Glaukos from $131.00 to $137.00 and gave the company a "buy" rating in a report on Thursday, August 1st. BTIG Research increased their price target on shares of Glaukos from $131.00 to $139.00 and gave the stock a "buy" rating in a research report on Wednesday, August 28th. Stifel Nicolaus lifted their price objective on Glaukos from $130.00 to $145.00 and gave the company a "buy" rating in a report on Tuesday, September 3rd. JPMorgan Chase & Co. upped their price objective on Glaukos from $130.00 to $145.00 and gave the company an "overweight" rating in a research note on Tuesday, November 5th. Finally, Wells Fargo & Company raised their target price on Glaukos from $135.00 to $145.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 5th. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $134.55.

Glaukos Price Performance

NYSE GKOS traded up $3.17 on Friday, hitting $144.00. 549,002 shares of the company were exchanged, compared to its average volume of 572,353. Glaukos Co. has a 1-year low of $59.22 and a 1-year high of $146.09. The firm has a 50 day moving average of $132.05 and a two-hundred day moving average of $123.31. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. The company has a market cap of $7.94 billion, a P/E ratio of -47.86 and a beta of 1.02.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.48) by $0.20. The firm had revenue of $96.70 million for the quarter, compared to analyst estimates of $91.50 million. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The business's quarterly revenue was up 23.9% compared to the same quarter last year. During the same period last year, the company earned ($0.50) EPS. On average, equities analysts predict that Glaukos Co. will post -1.96 EPS for the current year.

Insider Activity

In related news, Director Gilbert H. Kliman sold 3,000 shares of the company's stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $130.67, for a total value of $392,010.00. Following the completion of the sale, the director now owns 32,336 shares in the company, valued at approximately $4,225,345.12. This represents a 8.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, COO Joseph E. Gilliam sold 2,275 shares of the firm's stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total value of $316,156.75. Following the transaction, the chief operating officer now owns 102,169 shares in the company, valued at approximately $14,198,425.93. This trade represents a 2.18 % decrease in their position. The disclosure for this sale can be found here. Insiders own 6.40% of the company's stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.